Adductor Canal Block Versus Femoral Block on Pain and Quadriceps Strength

NCT05190120 | Completed Phase 4 Results FDA Drug

• 1 other identifier: 14-13071
• Study Type: interventional
• Target: 132
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the effects of a femoral nerve block vs. an adductor canal block on pain and quadriceps muscle strength for knee arthroscopy surgery.

Conditions

Anterior Cruciate Ligament Tear; Knee Meniscus Tear

Keywords

Knee arthroscopy; ACL reconstruction; Femoral block; Adductor Canal Block

Outcome Measures

Primary Outcomes (1)

• Change in Quadriceps Strength Related to the Nerve Block

  Quadriceps strength will be tested with a dynamometer before the nerve block and 20 minutes after the nerve block prior to surgery. The dynamometer measures the strength of the quadriceps muscles in the seated position while pushing against the device. We are trying to measure the effect of both femoral and adductor canal nerve blocks on quadriceps strength.

  Baseline and 20 minutes after the block prior to surgery

Secondary Outcomes (3)

• Numerical Pain Score From 0-10

  worse pain in first 24 hours

• Duration of Nerve Block

  8 to 24 hours

• Opioid Consumption Reported at mg of Morphine Equivalence

  2 days

Study Arms (2)

Femoral Block

ACTIVE COMPARATOR

Patients scheduled for knee arthroscopy will have a femoral nerve block done using 0.5% ropivacaine 20ml before surgery.

Procedure: Femoral Nerve Block; Drug: preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine

Adductor Canal Block

EXPERIMENTAL

Patients scheduled for knee arthroscopy will have an adductor canal block done using 0.75% ropivacaine 13.3ml before surgery.

Procedure: Adductor Canal Nerve Block; Drug: Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml.

Interventions

Femoral Nerve Block PROCEDURE

Patients having ACL reconstruction, meniscus surgery and knee arthroscopy

Femoral Block

Adductor Canal Nerve Block PROCEDURE

Patients having ACL reconstruction, meniscus surgery and knee arthroscopy

Adductor Canal Block

preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine DRUG

Femoral Block

Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml. DRUG

Adductor Canal Block

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• American Society of Anesthesia I-III classification,
• Scheduled for arthroscopic knee surgery (meniscal debridement/repair, ACL reconstruction)

You may not qualify if:

• Age younger than 18 years
• Non-English speaking
• Any contraindication for regional anesthesia, such as allergy to local anesthetics or opioids, -Coagulopaty or severe thrombocytopenia
• Infection at puncture sites
• Pre-existing neuropathy in operative limb
• Need for post-operative nerve function monitoring
• Dementia
• Patient refusal
• High pre-operative opioid requirements

Sponsors & Collaborators

• University of California, San Francisco: lead

Study Sites (1)

UCSF Orthopedic Trauma Service

San Francisco, California, 94158, United States

Location

MeSH Terms

Conditions

Anterior Cruciate Ligament Injuries

Interventions

Ropivacaine

Condition Hierarchy (Ancestors)

Knee Injuries; Leg Injuries; Wounds and Injuries

Intervention Hierarchy (Ancestors)

Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Limitations and Caveats

A longer length of study time due to periods of elapsed time without a clinical research investigator to continue and complete the study, extended length of study due to COVID-19 pandemic and inability to enroll patients for an extended period.

Results Point of Contact

• Title: Dr. Pedram Aleshi
• Organization: University of California San Francisco

pedram.aleshi@ucsf.edu

(415) 271-1627

Study Officials

• Pedram Aleshi, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 16, 2021
• First Posted: January 13, 2022
• Study Start: January 1, 2016
• Primary Completion: March 20, 2022
• Study Completion: March 20, 2022
• Last Updated: September 30, 2025
• Results First Posted: September 30, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)